About Temper Bio
Temper Bio’s mission is to translate breakthrough discoveries in neuro‑immune biology into new therapeutic strategies.
Temper Bio was founded by Rémi Soula, Sophie Ugolini, and Hervé Brailly, bringing together expertise in neuro-immunology, biotechnology entrepreneurship, and drug development. With the support of Argobio Studio, the company has built a therapeutic platform designed to restore immune balance in neuroinflammatory diseases.
The company builds on pioneering research from the Center of Immunology Marseille-Luminy (CIML), where the laboratory of Sophie Ugolini uncovered key roles for the neurokine TAFA4 in immune inflammatory cell control by neurons.
Today, the company is led by Osiris Marroquin Belaunzaran (CEO) and continues to work closely with its founders and scientific collaborators to advance its first biologic programs targeting the neuro-immune interface.